• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Lifshitz Law PLLC Announces Investigations of APRN, RENB, ICPT

    9/30/23 7:00:00 PM ET
    $APRN
    $ICPT
    $RENB
    Catalog/Specialty Distribution
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APRN alert in real time by email

    NEW YORK, Sept. 30, 2023 (GLOBE NEWSWIRE) --

    Renovaro Biosciences, Inc. (NASDAQ:RENB)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of RENB and GEDi Cube Intl Ltd. Under the terms of the proposed transaction, GEDi Cube Intl Ltd. equity interests will be exchanged for shares of RENB common stock through a stock-for-stock acquisition.

    If you are a RENB investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

    Blue Apron Holdings, Inc. (NASDAQ:APRN)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of APRN to Wonder Group for $13.00 per share in cash.

    If you are an APRN investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

    Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of ICPT to Alfasigma S.p.A for $19.00 per share in cash.

    If you are an ICPT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

    ATTORNEY ADVERTISING.© 2023 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

    Contact:

    Joshua M. Lifshitz, Esq.

    Lifshitz Law PLLC

    Phone: 516-493-9780

    Facsimile: 516-280-7376

    Email: [email protected] 



    Get the next $APRN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $APRN
    $ICPT
    $RENB

    CompanyDatePrice TargetRatingAnalyst
    Intercept Pharmaceuticals Inc.
    $ICPT
    7/13/2023$8.00 → $19.00Sell → Buy
    H.C. Wainwright
    Intercept Pharmaceuticals Inc.
    $ICPT
    6/29/2023$12.00 → $18.00Hold → Buy
    Canaccord Genuity
    Intercept Pharmaceuticals Inc.
    $ICPT
    5/23/2023Buy → Hold
    Needham
    Intercept Pharmaceuticals Inc.
    $ICPT
    5/22/2023$8.00Neutral → Sell
    H.C. Wainwright
    Intercept Pharmaceuticals Inc.
    $ICPT
    5/17/2023Outperform → Mkt Perform
    Raymond James
    Blue Apron Holdings Inc.
    $APRN
    8/10/2022$9.00Buy
    Lake Street
    Blue Apron Holdings Inc.
    $APRN
    7/21/2022$10.00Buy
    The Benchmark Company
    Intercept Pharmaceuticals Inc.
    $ICPT
    3/8/2022$31.00 → $29.00Hold
    Canaccord Genuity
    More analyst ratings

    $APRN
    $ICPT
    $RENB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs

      LOS ANGELES, April 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), an AI-driven precision Medicine Company that leverages AI platforms to improve outcomes for cancer and neurologically challenged patients, today announced is expanding our ongoing strategic collaboration with Nebul (www.nebul.com), a leading AI cloud infrastructure company, to advance the early detection of cancer and other diseases. The partnership aims to leverage Renovaro's deep learning and ML programs with Nebul's high-performance computing ("HPC") built on the latest platform to accelerate biomarker discovery and next-generation diagnostics. David Weinstein, CEO of Renovaro, stated, "By utilizing Nebul'

      4/22/25 9:20:00 AM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

      Strategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and Neurology LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced it closed its previously announced merger transaction with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and precision neurology company on April 8, 2025. Renovaro's merger with BioSymetrics is designed to enhance Renovaro's data repository and biomarker discovery capabilities, as well as add in vivo vali

      4/9/25 9:25:00 AM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovaro Provides Update to Definitive Agreement with Predictive Oncology

      LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today provided an update regarding its Definitive Agreement with Predictive Oncology Predictive Oncology, Inc. (NASDAQ:POAI) to initiate the previously announced integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States. Renovaro entered into a binding agreement merger agreement with Predictive Oncology, Inc. ("POI") dated January 1, 2025, and supplemented with the Extension Agreement dated February 28, 2025

      4/4/25 9:40:00 AM ET
      $POAI
      $RENB
      Industrial Specialties
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $APRN
    $ICPT
    $RENB
    Financials

    Live finance-specific insights

    See more
    • Blue Apron Announces Agreement to be Acquired by Wonder Group for $13.00 per Share

      Transaction Expected to Create a Leading Platform for Mealtime Focused on Quality and Flavor Across Meal Kits and Fully-Prepared Meal Experiences Blue Apron (NASDAQ:APRN) (the "Company"), the pioneer of the meal kit industry in the United States, today announced that it has entered into a definitive merger agreement to be acquired by Wonder Group ("Wonder"), a company founded by entrepreneur Marc Lore that is redefining at-home dining and food delivery. Under the terms of the merger agreement, which has been unanimously approved by Blue Apron's Board of Directors, Blue Apron stockholders will be entitled to receive $13.00 in cash per share of Class A common stock through a tender offer,

      9/29/23 7:00:00 AM ET
      $APRN
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Blue Apron Holdings, Inc. Reports Second Quarter 2023 Results

      Successfully Closes Strategic Transaction with FreshRealm and Eliminates Debt Defines Path to Adjusted EBITDA Profitability With Over 70% Year-over-Year Operating Cash Burn Reduction Blue Apron (NYSE:APRN) today announced financial results for the second quarter (2Q23) ended June 30, 2023. Second Quarter 2023 Highlights Net revenue of $106.2 million, a decrease of 6.1% sequentially and 14.5% year-over-year, largely driven by a one-time $10.0 million bulk sale to an enterprise customer recognized in the second quarter of 2022 (2Q22) and deliberate reduction in marketing spend Record customer engagement metrics, due in part to a price increase implemented in 2Q23 Average Order V

      8/9/23 6:30:00 AM ET
      $APRN
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Intercept to Announce Second Quarter 2023 Financial Results on August 2, 2023

      MORRISTOWN, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, will announce its second quarter 2023 financial results on Wednesday, August 2, 2023. The announcement will be followed by a conference call and audio webcast at 8:30 a.m. ET. Participants can access the conference call live via webcast which will be available on the investor page of the company's website at http://ir.interceptpharma.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the

      7/26/23 8:00:00 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APRN
    $ICPT
    $RENB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Intercept Pharma upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Intercept Pharma from Sell to Buy and set a new price target of $19.00 from $8.00 previously

      7/13/23 9:10:56 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intercept Pharma upgraded by Canaccord Genuity with a new price target

      Canaccord Genuity upgraded Intercept Pharma from Hold to Buy and set a new price target of $18.00 from $12.00 previously

      6/29/23 7:24:17 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intercept Pharma downgraded by Needham

      Needham downgraded Intercept Pharma from Buy to Hold

      5/23/23 7:40:07 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APRN
    $ICPT
    $RENB
    SEC Filings

    See more
    • Renovaro Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - RENOVARO INC. (0001527728) (Filer)

      4/18/25 5:00:41 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovaro Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events

      8-K - RENOVARO INC. (0001527728) (Filer)

      4/10/25 4:55:50 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovaro Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - RENOVARO INC. (0001527728) (Filer)

      2/28/25 4:05:41 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APRN
    $ICPT
    $RENB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner William Anderson Wittekind disposed of 350,000 shares, decreasing direct ownership by 9% to 3,353,878 units (SEC Form 4)

      4 - RENOVARO INC. (0001527728) (Issuer)

      3/12/25 8:12:50 AM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Van Tilburg Maurice was granted 250,000 shares (SEC Form 4)

      4 - RENOVARO INC. (0001527728) (Issuer)

      2/25/25 1:33:34 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Fuentes Nathen

      4 - RENOVARO INC. (0001527728) (Issuer)

      2/25/25 1:29:46 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APRN
    $ICPT
    $RENB
    Leadership Updates

    Live Leadership Updates

    See more
    • Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

      Strategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and Neurology LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced it closed its previously announced merger transaction with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and precision neurology company on April 8, 2025. Renovaro's merger with BioSymetrics is designed to enhance Renovaro's data repository and biomarker discovery capabilities, as well as add in vivo vali

      4/9/25 9:25:00 AM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sleep Number Board Names Linda Findley as President and Chief Executive Officer

      Findley has a demonstrated record of accelerating growth and transformation across diverse consumer business models Phillip Eyler to become independent Board Chair, effective after the 2025 Annual Meeting of Shareholders Sleep Number Corporation (NASDAQ:SNBR) today announced that its Board of Directors (the "Board") has appointed Linda Findley as the company's new President and Chief Executive Officer, and as a member of the Board, effective April 7, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250305807579/en/Linda Findley will assume the role of Sleep Number President and CEO on April 7, 2025 (Photo: Business Wire) Fi

      3/5/25 4:15:00 PM ET
      $APRN
      $ETSY
      $RL
      $SNBR
      Catalog/Specialty Distribution
      Consumer Discretionary
      Business Services
      Apparel
    • Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine

      Strategic Combination Aims to Accelerate Biomarker Identification, Enhance Drug Discovery, and Expand Precision Medicine Applications in Cancer and Beyond LOS ANGELES, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced a definitive agreement to merge with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and biomarker identification company. This transformative partnership is designed to enhance Renovaro's data repository, biomarker discovery capabilities, accelerate translational research, and bring precision medicin

      2/26/25 1:25:00 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APRN
    $ICPT
    $RENB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Renovaro Inc.

      SC 13D/A - RENOVARO INC. (0001527728) (Subject)

      11/6/24 5:45:52 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Renovaro Inc.

      SC 13D/A - RENOVARO INC. (0001527728) (Subject)

      10/24/24 8:57:01 AM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Renovaro Inc.

      SC 13D/A - RENOVARO INC. (0001527728) (Subject)

      6/24/24 7:56:04 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APRN
    $ICPT
    $RENB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for OCALIVA issued to INTERCEPT PHARMS INC

      Submission status for INTERCEPT PHARMS INC's drug OCALIVA (SUPPL-8) with active ingredient OBETICHOLIC ACID has changed to 'Approval' on 02/24/2022. Application Category: NDA, Application Number: 207999, Application Classification: Labeling

      2/25/22 4:36:46 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for OCALIVA issued to INTERCEPT PHARMS INC

      Submission status for INTERCEPT PHARMS INC's drug OCALIVA (SUPPL-7) with active ingredient OBETICHOLIC ACID has changed to 'Approval' on 05/26/2021. Application Category: NDA, Application Number: 207999, Application Classification: Labeling

      5/27/21 5:23:24 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care